Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells.
about
The health benefits of vitamin KVitamin K and hepatocellular carcinoma: The basic and clinicHepatocyte RXRalpha deficiency in matured and aged mice: impact on the expression of cancer-related hepatic genes in a gender-specific mannerSynergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells.Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.Retinoids and rexinoids in cancer prevention: from laboratory to clinic.Synergistic Effects of PPARgamma Ligands and Retinoids in Cancer Treatment.Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis.Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis.Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids.Retinoic acid and cAMP inhibit rat hepatocellular carcinoma cell proliferation and enhance cell differentiation.Phosphorylated retinoid X receptor alpha loses its heterodimeric activity with retinoic acid receptor beta.Peretinoin, an acyclic retinoid, inhibits hepatocarcinogenesis by suppressing sphingosine kinase 1 expression in vitro and in vivo.Synergistic growth inhibition in HL-60 cells by the combination of acyclic retinoid and vitamin K2.Combination of acyclic retinoid with branched-chain amino acids inhibits xenograft growth of human hepatoma cells in nude mice.Research progress on the anticancer effects of vitamin K2.
P2860
Q26782816-27CC07FA-36AE-40F4-A8FF-12817F6D71BAQ26783713-4689108F-99D9-4C44-8B66-E33887FF5000Q33364577-C6B863A4-589C-4316-9570-EC5B66C1B5AAQ35011302-70AB971E-0698-4E69-9377-8B61AAF71B53Q36223025-2DDE0EEC-893A-4257-B7DA-5537E439C17EQ36680198-739D4B98-2526-4410-845A-E26708E611A1Q37182802-2AA41BCE-8405-4579-A4C8-D7A0BB2CAEA6Q38040323-07510380-5733-4DCD-89B3-3184966BE81DQ38066478-59D6F5B3-59DA-422C-A223-E222E68CC62FQ38165918-948CC79D-CDEC-4D0C-89A0-49DF87FF4ABBQ39343994-0AC382AB-B87F-45A4-A03C-64CDCF01BA37Q40075358-3DF96EF1-EC55-4356-900B-DB0808ADB864Q47167981-DD99ECC2-709A-462B-8444-011868E7AFF9Q50443179-E71FD224-D66B-4830-8CED-25BE2FA39A1FQ54282221-36D38946-29D2-4B1F-9F5E-A5BF0448E612Q55261096-660F4810-73C8-46B8-835E-0E3A2311A6DE
P2860
Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Synergistic growth inhibition ...... epatocellular carcinoma cells.
@en
type
label
Synergistic growth inhibition ...... epatocellular carcinoma cells.
@en
prefLabel
Synergistic growth inhibition ...... epatocellular carcinoma cells.
@en
P2093
P2860
P1433
P1476
Synergistic growth inhibition ...... epatocellular carcinoma cells.
@en
P2093
Hisashi Tsurumi
Hisataka Moriwaki
Masahito Shimizu
Masataka Okuno
Rie Matsushima-Nishiwaki
Toh Kanamori
P2860
P304
P356
10.1111/J.1349-7006.2006.00384.X
P577
2007-03-01T00:00:00Z